Colchicine for symptomatic coronary artery disease after percutaneous coronary intervention
Open Heart
JANUARY 6, 2022
Background Percutaneous coronary intervention (PCI), the preferred coronary reperfusion strategy, induces endothelial trauma which may mount an inflammatory response. This has been shown to increase the likelihood of further major adverse cardiovascular events (MACE). Colchicine, a cheap and widely used anti-inflammatory has shown promise in improving cardiovascular outcomes.
Let's personalize your content